Capricor Therapeutics, Inc. (CAPR)
6.81
+0.52
(+8.27%)
USD |
NASDAQ |
Aug 24, 16:00
6.80
-0.01
(-0.15%)
After-Hours: 20:00
Capricor Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2024 | 96.62% |
| September 30, 2024 | 84.03% |
| June 30, 2024 | 91.01% |
| March 31, 2024 | 93.25% |
| December 31, 2023 | 97.46% |
| September 30, 2023 | 95.53% |
| June 30, 2023 | 93.66% |
| March 31, 2023 | 92.51% |
| December 31, 2022 | 80.72% |
| September 30, 2022 | 89.96% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 89.47% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| REGENXBIO, Inc. | 95.56% |
| Cytokinetics, Inc. | 67.78% |
| Emergent BioSolutions, Inc. | 51.22% |
| Rigel Pharmaceuticals, Inc. | 89.17% |
| Ironwood Pharmaceuticals, Inc. | 99.60% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -63.47% |
| Return on Assets | -49.21% |
| Return on Invested Capital | -55.21% |
| Return on Net Operating Assets | -278.2% |